RT Journal Article
SR Electronic
T1 Increase in diagnoses associated with Post Acute Sequelae of COVID-19 (PASC) before and during the COVID-19 pandemic: a case-control study in the total population of Region Stockholm
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.07.24308594
DO 10.1101/2024.06.07.24308594
A1 Lindberg, Pia
A1 Ljunggren, Gunnar
A1 Lee, Seika
A1 Kolosenko, Iryna
A1 Runold, Michael
A1 Piontkovskaya, Kristina
A1 Wachtler, Caroline
A1 Wheelock, Åsa M.
A1 Carlsson, Axel C.
YR 2024
UL http://medrxiv.org/content/early/2024/06/08/2024.06.07.24308594.abstract
AB Objectives Post Acute Sequele of COVID-19 (PASC) is a remaining health concern after the pandemic. We aimed to investigate the prevalence of diagnoses and symptom diagnoses recorded before and during the pandemic in individuals who later received PASC.Methods A case-control study was designed to investigate the prevalence of registered diagnoses in adult, non-hospitalized PASC patients (cases) 2019, 12 months before and 6 months after the PASC diagnosis compared to matched controls. Data was extracted from the Stockholm Region’s data warehouse (VAL).Results Results indicate higher diagnosis rates for men and women with PASC already in 2019 and 12 months before diagnosis; slightly decreasing 6 months after PASC. Cases showed more pre-pandemic respiratory diagnoses compared to controls. In 2019, cases had higher rates of acute upper respiratory tract infection (OR 2.47 for men, 2.22 for women), asthma (OR 1.76 (men), 1.95 (women)), and bronchitis (OR 2.15 (men), 2.71 (women)) than controls.Conclusions The present study showed that individuals who later developed PASC were more likely than others to show respiratory symptoms before COVID-19. Pre-existing vulnerabilities observed before the pandemic in those later diagnosed with PASC in 2021 suggest a potential link between prior conditions and PASC development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Region Stockholm FoUI-97300, Swedish Heart-lung foundation, and Swedish Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swedish Ethical Review Authority gave Ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptPASCPost Acute Sequelae of COVID-19VALStockholm Regional Health Care Data WarehouseICD-10International Classification of Diseases, 10th editionORodds ratioCIconfidence interval.